Cargando…
Meeting the Unmet Need in the Management of MDR Gram-Positive Infections with Oral Bactericidal Agent Levonadifloxacin
Levonadifloxacin (intravenous) and its oral prodrug alalevonadifloxacin are broad-spectrum antibacterial agents developed for the treatment of difficult-to-treat infections caused by multidrug-resistant Gram-positive bacteria, especially methicillin-resistant Staphylococcus aureus, atypical bacteria...
Autores principales: | Mehta, Yatin, Mishra, K. C., Paliwal, Yashesh, Rangappa, Pradeep, Sinha, Sharmili, Bhapkar, Sandeep |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9922174/ https://www.ncbi.nlm.nih.gov/pubmed/36785544 http://dx.doi.org/10.1155/2022/2668199 |
Ejemplares similares
-
Real-World Evidence of Efficacy and Safety of Levonadifloxacin (Oral and IV) in the Management of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Findings of a Retrospective, Multi-Center Study
por: Mehta, Kapil D, et al.
Publicado: (2022) -
Efficient Synthesis of Potential Impurities in Levonadifloxacin
(WCK 771)
por: Kilbile, Jaydeo T., et al.
Publicado: (2021) -
Prescription-Event Monitoring Study on Safety and Efficacy of Levonadifloxacin (Oral and I.V.) in Management of Bacterial Infections: Findings of Real-World Observational Study
por: Mehta, Yatin, et al.
Publicado: (2022) -
Meeting the unmet needs of family planning
por: Choudhary, Deepti
Publicado: (2016) -
In Vitro activity of a Novel Benzoquinolizine Antibiotic, Levonadifloxacin (WCK 771) against Blood Stream Gram-Positive Isolates from a Tertiary Care Hospital
por: Mamtora, Dhruv, et al.
Publicado: (2020)